Premium
The role of HSP27 in the development of drug resistance of gastrointestinal malignancies: Current status and perspectives
Author(s) -
Soleimani Atena,
JaliliNik Mohammad,
Avan Amir,
Ferns Gordon A.,
Khazaei Majid,
Hassanian Seyed Mahdi
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.27666
Subject(s) - current (fluid) , drug resistance , gastrointestinal cancer , drug , drug development , hsp27 , medicine , intensive care medicine , cancer research , immunology , cancer , biology , pharmacology , microbiology and biotechnology , colorectal cancer , genetics , engineering , gene , heat shock protein , hsp70 , electrical engineering
Heat‐shock protein 27 (HSP27) is a chaperone molecule that plays a critical role in the refolding and activity of several proteins responsible for cancer cell drug toxicity. Upregulation of HSP27 is associated with decreased drug sensitivity as well as poorer survival in gastrointestinal (GI) malignancies. It is, therefore, possible that HSP27 may be of value in the assessment of prognostic and therapeutic efficacy in the treatment of GI cancers. Pharmacological and biological inhibitors of HSP27 enhance tumor cell chemosensitivity. This review summarizes the potential role of HSP27 in chemotherapy drug resistance and the therapeutic potential of HSP27 inhibitors as a novel strategy in the treatment of GI cancers.